Ignite Creation Date:
2025-12-25 @ 5:12 AM
Ignite Modification Date:
2026-03-16 @ 10:14 PM
Study NCT ID:
NCT00901927
Status:
TERMINATED
Last Update Posted:
2020-04-03
First Post:
2009-05-12
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Bendamustine, Mitoxantrone, and Rituximab (BMR) for Patients With Untreated High Risk Follicular Lymphoma
Sponsor:
M.D. Anderson Cancer Center
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Follicular Lymphoma | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | Lymphoma | View |
| None | Non-Hodgkin's Lymphoma | View |
| None | Untreated High Risk Follicular Lymphoma | View |
| None | Bendamustine hydrochloride | View |
| None | Bendamustine HCI | View |
| None | Bendamustine | View |
| None | CEP-18083 | View |
| None | SDX-105 | View |
| None | Treanda | View |
| None | Mitoxantrone | View |
| None | Novantrone | View |
| None | Rituximab | View |
| None | Rituxan | View |